Immunosuppression and melanocyte proliferation

Melanoma Research

Volumn 19, Issue 2, 2009, Pages 63-68

  Zattra, Edoardo ^a   Fortina, Anna Belloni ^b   Bordignon, Matteo ^b   Piaserico, Stefano ^b   Alaibac, Mauro ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; AZATHIOPRINE; BETA CATENIN; CALCINEURIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ENDOTHELIN 3; ENDOTHELIN B RECEPTOR; ETANERCEPT; FLUOROURACIL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERMEDIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PREDNISONE; SCATTER FACTOR; STEM CELL FACTOR; STEROID; TACROLIMUS; TYROSINASE RELATED PROTEIN 1; UNINDEXED DRUG; UVOMORULIN; ANTINEOPLASTIC AGENT; CYTOKINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATOPIC DERMATITIS; AUTOCRINE EFFECT; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CROHN DISEASE; CYTOKINE PRODUCTION; DOWN REGULATION; ERUPTIVE NEVUS; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; IMMUNE SYSTEM; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE MELANOMA; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; LYMPHOPROLIFERATIVE DISEASE; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; NEVUS; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN CARCINOGENESIS; SKIN DISEASE; SOLID TUMOR; VITILIGO; CELL DIVISION; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE PREDISPOSITION; DRUG EFFECT; IMMUNE DEFICIENCY; IMMUNOLOGY; NEURAL CREST; PATHOLOGY; PHYSIOLOGY; PIGMENTED NEVUS; POSTOPERATIVE COMPLICATION; TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MELANOCYTE-STIMULATING HORMONES; MELANOCYTES; MELANOMA; NEURAL CREST; NEVUS, PIGMENTED; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION; VITILIGO;

EID: 65449173962     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328322fc20     Document Type: Review

References (90)

1. Bennett DC. Genetics, development, and malignancy of melanocytes. Int Rev Cytol 1993; 146:191-260.
2. Murphy M, Reid K, Dutton R, Brooker G, Bartlett PF. Neural stem cells. J Investig Dermatol Symp Proc 1997; 2:8-13.
3. Hau P, Ruemmele P, Kunz-Schughart LA, Doerfelt A, Hirschmann B, Lohmeier A, et al. Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma. Oncol Rep 2004; 12:1355-1364.
4. Broxmeyer HE, Maze R, Miyazawa K, Carow C, Hendrie PC, Cooper S, et al. The kit receptor and its ligand, steel factor, as regulators of hemopoiesis. Cancer Cell 1991; 3:480-487.
5. Grichnik JM, Crawford J, Jiminez F, Kurtzberg J, Buchanan M, Blackwell S, et al. Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients. J Am Acad Dermatol 1995; 33:577-583.
6. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-KIT proto-oncogene receptor. Int J Cancer 1992; 52 :197-201.
7. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC. Non-hematopoietic tumor cell lines express stem cell factor and display c-KIT receptors. Blood 1992; 80:374-381.
8. Takahasi H, Saitoh K, Kishi H, Parsons PG. Immunohistochemical localization of stem cell factor (SCF) with comparison of its receptor c-KIT proto-oncogene product (c-kit) in melanocytic tumors. Virchows Arch 1995; 427:283-288.
9. Herlyn M, Berking C, Li G, Satyamoorthy K. Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Res 2000; 1:303-312.
10. Nordlund JJ. The melanocyte and the epidermal melanin unit: an expanded concept. Dermatol Clin 2007; 25:271-281.
11. Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res 2000; 13:4-14.
12. Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 2005; 18 :150-159.
13. Vleminckx K, Kemler R. Cadherins and tissue formation: integrating adhesion and signaling. BioEssays 1999; 21:211-220.
14. Danen EH, de Vries TJ, Morandini R, Ghanem GG, Ruiter DJ, Van Muijen GN. E-cadherin expression in human melanoma. Melanoma Res 1996; 6 :127-131.
15. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signalling in an adhesion-independent manner. J Cell Biol 2001; 153:1049-1060.
16. DeLuca SM, Gerhart J, Cochran E, Simak E, Blitz J, Mattiacci-Paessler M, et al. Hepatocyte growth gactor/scatter factor promotes a switch from E-cadherin to N-cadherin in chick embryo epiblast cells. Exp Cell Res 1999; 251:3-15.
17. Tada A, Suzuki I, Im S, Davis MB, Cornelius J, Babcock G, et al. Endothelin-1 is a paracrine growth factor that modulates melanogenesis of human melanocytes and participates in their responses to ultraviolet radiation. Cell Growth Differ 1998; 9:575-584.
18. Scott GA, Cassidy L. Rac1 mediates dendrite formation in response to melanocyte stimulating hormone and UV light in murine melanoma model. J invest Dermatol 1998; 111:243-250.
19. Halaban R, Ghosh S, Duray P, Kirkwood JM, Lerner AB. Human melanocyte cultured from nevi and melanomas. J Invest Dermatol 1986; 87:95-101.
20. Halaban R, Rubin JS, White W. met and HGF-SF in normal melanocytes and melanoma cells. EXS 1993; 65:329-339.
21. Halaban R, Ghosh S, Baird A. bFGF in the putative natural growth factor for human melanocytes. In Vitro Cell Dev Biol 1987; 23:47-52.
22. Bordoni R, Fine R, Murray D, Richmond A. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes. J Cell Biochem 1990; 44 :207-219.
23. Terashi H, Itami S, Tadokoro T, Takeyama M, Katagiri K, Takayasu S. Growth stimulation of normal melanocytes and nevocellular nevus by gastrin releasing peptide (GRP). J Dermatol Sci 1998; 17:93-100.
24. Catania A, Airaghi L, Colombo G, Lipton JM. Alpha-melanocyte-stimulating hormone in normal human physiology and disease states. Trends Endocrinol Metab 2000; 11:304-308.
25. Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R. The melanocortin 1 receptor and the UV response of human melanocytes - a shift in paradigm. Photochem Photobiol 2008; 8:501-508.
26. Swope VB, Medrano EE, Smalara D, Abdel-Malek ZA. Long term proliferation of human melanocytes is supported by the physiologic mitogens a-melanotropin, endothelin-1 and basic fibroblast growth factor. Exp Cell Res 2000; 217:435-459.
27. Eves PC, MacNeil S, Haycock JW. Alpha-Melanocyte stimulating hormone, inflammation and human melanoma. Peptides 2006; 27:444-452.
28. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998.
29. Barker JN, MacDonald DM. Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol 1988; 13:123-125.
30. Richert S, Bloom EJ, Flynn K, Seraly MP. Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myalocytic leukaemia: a case report and review of the literature. Am Acad Dermatol 1996; 35 :326-329.
31. Duvic M, Lowe L, Rapini RP, Rodriguez S, Levy ML. Eruptive dysplastic rruptive dysplastic nevi associated with human immunodeficiency virus infection. Arch Dermatol 1989; 125:397-401.
32. Huges B, Cunliffe WJ, Bailey CC. Excess benign melanocytic nevi in children after chemotherapy for malignancy in childhood. Br Med J 1989; 299:88-91.
33. De Wit PE, de Vaan GA, de Boo TM, Lemmens WA, Rampen FH. Prevalence of naevocytic naevi after chemotherapy for childhood cancer. Med Pediatr Oncol 1990; 18:336-338.
34. Smith CH, McGregor JM, Barker JN, Morris RW, Rigden SP, MacDonald DM. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol 1993; 28:51-55.
35. McGregor JM, Barker JN, MacDonald DM. The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. Clin Exp Dermatol 1991; 16:131-132.
36. Piaserico S, Alaibac M, Fortina AB, Peserico A. Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. J Am Acad Dermatol 2006; 54:338-340.
37. Alaibac M, Piaserico S, Rossi CR, Foletto M, Zacchello G, Carli P, et al. Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J Am Acad Dermatol 2003; 4:1020-1022.
38. Belloni Fortina A, Piaserico S, Zattra E, Alaibac M. Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn's disease. Melanoma Res 2005; 15:223-224.
39. Page EH, Wexler DM, Guenther LC. Cyclosporin A. J Am Acad Dermatol 1986; 14:785-791.
40. Griffiths CE, Katsambas A, Dijkmans BA, Finlay AY, Ho VC, Johnston A, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol 2006; 155 (Suppl 2):1-16.
41. Italia JL, Bhardwaj V, Kumar MN. Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. Drug Discov Today 2006; 11 :846-854.
42. Brady AJ, Wing AJ. Hyperpigmentation due to cyclosporin therapy. Nephrol Dial Transplant 1989; 4:309-310.
43. Ozkaya-Bayazit E, Diz-Kucukkaya R, Akasya E, Buyukbabani N, Oncu S, Pekcelen Y. Bullous acral erythema and concomitant pigmentation on the face and occluded skin. J Eur Acad Dermatol Venereol 2000; 14:139-140.
44. Lee JY, Kang WK. Effect of cyclosporin A on melanogenesis in cultured human melanocytes. Pigment Cell Res 2003; 16:504-508.
45. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006; 55:369-389.
46. Rogatsky I, Hittelman AB, Pearce D, Garabedian MJ. Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids. Mol Cell Biol 1999; 19:5036-5049.
47. Jackson S, Gilchrist H, Nesbitt LT Jr. Update on the dermatologic use of systemic glucocorticosteroids. Dermatol Ther 2007; 20:187-205.
48. Madan V, Griffiths CE. Systemic cyclosporin and tacrolimus in dermatology. Dermatol Ther 2007; 20:239-250.
49. McCormack PL, Keating GM. Tacrolimus: in heart transplant recipients. Drugs 2006; 66:2269-2279. Discussion 2280-2282
50. Kang HY, Choi YM. FK506 increases pigmentation and migration of human melanocytes. Br J Dermatol 2006; 155:1037-1040.
51. Lan CC, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005; 153:498-505.
52. Fukushima S, Hatta N. Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug. Br J Dermatol 2004; 151:698-700.
53. Bogenrieder T, Weitzel C, Scholmerich J, Landthaler M, Stolz W. Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology 2002; 205:174-175.
54. Sobell JM. Overview of biologic agents in medicine and dermatology. Semin Cutan Med Surg 2005; 24:2-9.
55. Weinberg JM, Bottino CJ, Lindholm J, Buchholz R. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. J Drugs Dermatol 2005; 4:544-555.
56. Koo J, Khera P. Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci 2005; 38:75-87.
57. Bovenschen HJ, Tjioe M, Vermaat H, de Hoop D, Witteman BM, Janssens RW, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 2006; 154:880-884.
58. Katsanos KH, Christodoulou DK, Zioga A, Tsianos EV. Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence? Inflamm Bowel Dis 2003; 9:279.
59. Smith KJ, Skelton HG, Heimer W, Baxter D, Angritt P, Frisman D, et al. Melanocytic activation in HIV-1 disease: HMB-45 staining in common acquired nevi. Military Medical Consortium for the Advancement of Retroviral Research. J Am Acad Dermatol 1993; 29:539-544.
60. Betlloch I, Amador C, Chiner E, Pasquau F, Calpe JL, Vilar A. Eruptive melanocytic nevi in human immunodeficiency virus infection. Int J Dermatol 1991; 30:303.
61. Grob JJ, Bastuji-Garin S, Vaillant L, Roujeau JC, Bernand P, Sassolas B, et al. Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients. J Invest Dermatol 1996; 107:694-697.
62. Pantanowitz L, Schlecht HP, Dezube BJ. The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol 2006; 18:469-478.
63. Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 2000; 15:1712-1728.
64. Haddad JJ, Saadé NE, Safieh-Garabedian B. Interleukin-10 and the regulation of mitogen-activated protein kinases: are these signalling modules targets for the anti-inflammatory action of this cytokine? Cell Signal 2003; 15 :255-267.
65. Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, et al. Effects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation. Int Immunopharmacol 2006; 20:2011-2017.
66. Daniel V, Naujokat C, Sadeghi M, Wiesel M, Hergesell O, Opelz G. Association of circulating interleukin (IL)-12 and IL-10-producing dendritic cells with time posttransplant, dose of immunosuppression, and plasma cytokines in renal-transplant recipients. Transplantation 2005; 15:1498-1506.
67. Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16:471-478.
68. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006; 203:1651-1656.
69. Vance K, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 2004; 17:318-325.
70. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005; 17:764-769.
71. Schiller M, Brzoska T, Böhm M, Metze D, Scholzen TE, Rougier A, et al. Solar-simulated ultraviolet radiation-induced upregulation of the melanocortin-1 receptor, proopiomelanocortin, and alpha-melanocyte-stimulating hormone in human epidermis in vivo. J Invest Dermatol 2004; 122:468-476.
72. Luger TA, Brzoska T. Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis 2007; 66 (Suppl 3):iii52-iii55.
73. Cooper A, Robinson SJ, Pickard C, Jackson CL, Friedmann PS, Healy E. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol 2005; 1:4806-4813.
74. Taylor AW. Modulation of regulatory T cell immunity by the neuropeptide alpha-melanocyte stimulating hormone. Cell Mol Biol (Noisy-le-grand) 2003; 49:143-149.
75. Riker AI, Radfar S, Liu S, Wang Y, Khong HT. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 2007; 7:345-358.
76. Cebon J, Gedye C, John T, Davis ID. Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 2007; 5:994-1006.
77. Dinh QQ, Chong AH. Melanoma in organ transplant recipients: the old enemy finds a new battleground. Australasian J Dermatol 2007; 48:199-207.
78. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000; 143:513-519.
79. Berg D, Otley CC. Skin cancer in organ transplant recipients. Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1-17.
80. Belloni-Fortina A, Piaserico S, Caforio AL, Abeni D, Alaibac M, Angelini A, et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 2004; 140:1079-1085.
81. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137:459-463.
82. Taieb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20:27-35.
83. Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, Kemp EH, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008; 17:139-140.
84. Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol 2007; 21 :865-876.
85. Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 2006; 90 :215-241.
86. Jacobs JF, Aarntzen EH, Sibelt LA, Blokx WA, Boullart AC, Gerritsen MJ, et al. Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 2009; 58 :145-151.
87. Kim SM, Lee HS, Hann SK. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999; 38:546-550.
88. Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004; 51:760-766.
89. Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs 2005; 65:447-459.
90. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51:52-61.